ContraVir Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, has named John Cavan as chief financial officer. Mr. Cavan had served as the company’s interim CFO since January 2016. “John is an accomplished executive with significant financial and operational expertise within the biotechnology industry, and we are pleased to have him assume this key executive role,” said James Sapirstein, chief executive off...